Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Eosinophilic granulomatosis with polyangiitis
Questions discussed in this category
Which EGPA patients are most likely to benefit from treatment with anti-IL-5 agents such as mepolizumab?
1 Answer available
8885
Papers discussed in this category
The New England journal of medicine, 2017-05-18
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Related Topics
Rheumatology
Vasculitis
Pulmonology
Mepolizumab
IL-5 Inhibitors
EGPA
Churg-Strauss
